The efficacy and tolerability of other Nrp1-targeting drugs should be considered, and since Nrp1 plays so many roles in the glioma microenvironment (Figure 3), pursuing research in the development and implementation of Nrp1 antagonists in glioma therapy seems fruitful. The gene discussed is NRP1; the disease is central nervous system cancer.